Related Experiment Video
Updated: Sep 12, 2025
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Post-encephalitic epilepsy in patients with acute encephalopathy with biphasic seizures and late reduced diffusion
Kota Nagai1, Go Kawano1, Hirotaka Sakaguchi1
1Department of Paediatrics, St Mary's Hospital, Fukuoka, Japan.
Insights
Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) can lead to post-encephalitic epilepsy (PEE). Therapeutic hypothermia, particularly Early-Hypo or Late-Hypo, significantly reduced PEE risk in AESD patients.
Area of Science:
- Pediatric Neurology
- Infectious Diseases
- Neuroscience
Background:
- Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a common cause of pediatric encephalopathy.
- AESD often leads to neurological deficits, including post-encephalitic epilepsy (PEE).
Purpose of the Study:
- To determine the incidence of PEE in children with AESD.
- To evaluate the efficacy of therapeutic hypothermia in reducing PEE risk.
Main Methods:
- Retrospective study of 45 AESD patients treated between July 2008 and April 2024.
- Comparison of PEE incidence between patients who received therapeutic hypothermia (Early-Hypo, Late-Hypo) and those who did not (Non-Hypo).
Main Results:
- The overall prevalence of PEE was 26.7% (12/45 patients).
- Higher Tada scores were identified as an independent risk factor for PEE.
- Therapeutic hypothermia (Early-Hypo or Late-Hypo) significantly reduced the risk of PEE.
Conclusions:
- Higher Tada scores are associated with an increased risk of PEE in AESD patients.
- Therapeutic hypothermia is an effective intervention for reducing PEE risk in AESD.
Introduction:
Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a prevalent form of acute infection-triggered encephalopathy in children, excluding the unclassified type. It is marked by febrile seizures, referred to as early seizures and subsequent late seizures, along with a reduction in the apparent diffusion coefficient in cortical or subcortical white matter. AESD frequently results in neurological sequelae, including post-encephalitic epilepsy (PEE).
Methods:
This retrospective study examined the incidence of PEE and investigated whether therapeutic hypothermia reduced the risk of PEE in 45 patients with AESD treated at St Mary's Hospital between July 2008 and April 2024. Patients whose Glasgow Coma Scale score was >8 and who had mild clinical symptoms, as judged by the attending physician, between July 2008 and December 2020, did not undergo therapeutic hypothermia. However, all patients with AESD underwent therapeutic hypothermia during the period between January 2021 and April 2024. There were 11, 24, and 10 patients in the Early-Hypo, Late-Hypo, and Non-Hypo groups, respectively.
Results:
The prevalence of PEE among patients with AESD was 26.7% (12 out of 45 patients), with a median observation period of 75 months (IQR 37-98 months, range 20-182 months). Univariate analysis revealed statistically significant differences between patients with and without PEE in several factors, including Glasgow Coma Scale scores between 12 and 24 h after early seizures, and the number of patients with AESD with biphasic course, Tada scores, and the Pediatric Cerebral Performance Category at 6 months post-onset. Multivariate logistic regression analysis identified higher Tada scores as an independent risk factor for developing PEE, and the treatment options of Early-Hypo or Late-Hypo significantly reduced the risk of PEE.
Conclusion:
While further prospective studies with larger cohorts are warranted, this study highlights the association between higher Tada scores and an increased risk of PEE in patients with AESD, and the treatment options of Early-Hypo or Late-Hypo significantly reduced the risk of PEE.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:13Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:14Antiepileptic Drugs: Glutamate Antagonists